The chestnut tree (Castanea sativa Mill.) is a species widely cultivated in Portugal, which is a major producer of chestnuts. Nuts are nutritionally interesting, not only because of their content of vitamins, minerals, and phytochemicals but also of their high fiber content. Fiber, as it is not digested by humans, has a preponderant role in the intestinal microbiota, for its maintenance, and, consequently, has an impact on metabolic status. The inclusion of foods rich in these components, and with extensive local production, can be an excellent strategy for improving the metabolic parameters of the population. The main objective of this single group assignment clinical trial is to evaluate the effect of including roasted chestnuts in the daily diet on the composition and diversity of the intestinal microbiota. It is also intended to evaluate metabolic parameters to determine the impact of this intervention.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
33
Daily consumption of roasted chestnut (150g) for 14 days
Nova Medical School Universidade Nova de Lisboa
Lisbon, Portugal
RECRUITINGChanges in Gut microbiota characterization
Difference in Gut microbiota taxonomic characterization, from baseline to the end of intervention
Time frame: 14 days
Changes in Gut microbiota diversity
Difference in Gut microbiota Shannon index, from baseline to the end of intervention
Time frame: 14 days
Changes in fasting glucose
Changes in fasting glucose, measured in mg/dL, from baseline to end of intervention
Time frame: 14 days
Changes in HOMA-IR
Changes in HOMA-IR from baseline to end of intervention
Time frame: 14 days
Changes in total cholesterol
Changes in total cholesterol, measured in mg/dL, from baseline to end of intervention
Time frame: 14 days
Changes in LDL cholesterol
Changes in LDL cholesterol, measured in mg/dL, from baseline to end of intervention
Time frame: 14 days
Changes in high sensitivity PCR
Changes in high sensitivity PCR, measured in mg/dL, from baseline to end of intervention
Time frame: 14 days
Changes in breath H2
Changes in breath H2, measured in ppm, from baseline to end of intervention
Time frame: 14 days
Changes in breath CH4
Changes in breath CH4, measured in ppm, from baseline to end of intervention
Time frame: 14 days
Changes in fecal butyrate
Changes in fecal butyrate, measured in M, from baseline to end of intervention
Time frame: 14 days
Changes in fecal acetate
Changes in fecal acetate, measured in M, from baseline to end of intervention
Time frame: 14 days
Changes in fecal ALP
Changes in fecal ALP, measured in mg/g feces, from baseline to end of intervention
Time frame: 14 days
Changes in fecal LPS
Changes in fecal LPS, measured in EU/mL , from baseline to end of intervention
Time frame: 14 days
Changes in IL-1b
Changes in IL1b, measured in pg/mL , from baseline to end of intervention
Time frame: 14 days
Changes in TNFa
Changes in TNFa, measured in pg/mL , from baseline to end of intervention
Time frame: 14 days
Changes in adiponectin
Changes in adiponectin, measured in ng/mL , from baseline to end of intervention
Time frame: 14 days
Changes in leptin
Changes in leptin, measured in ng/mL , from baseline to end of intervention
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.